Careers
Foghorn Cuts Headcount From 106 to 65 After Eli Lilly Exits Their Cancer Collaboration
The partners halted FHD-909 following Phase 1 dose-escalation data, and Foghorn says its remaining cash funds operations into the second half of 2029.
DW
By Dana Whitfield
Oct 3, 2026 · 2 min read
Foghorn Therapeutics is cutting about 40% of its workforce, reducing full-time headcount from 106 to 65, after Eli Lilly ended the companies' oncology collaboration.
Discussion (0)
Sign in to join the discussion.
Loading comments…
DW
Dana Whitfield
Leadership Editor
Dana reports on boards, succession and executive pay. She has interviewed more than 200 sitting chief executives.